Hydroxyzine Hydrochloride
NDC Package 68071-4530-3
Package Information
Hydroxyzine Hydrochloride is for symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus.As a sedative when used as a premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Marketed by Nucare Pharmaceuticals,inc., this product is identified by NDC 68071-4530 and is authorized under FDA application ANDA088618.
Identification & Billing
- RxCUI: 995258 - hydrOXYzine HCl 25 MG Oral Tablet
- RxCUI: 995258 - hydroxyzine hydrochloride 25 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 68071 - Nucare Pharmaceuticals,inc.
- 68071-4530 - Hydroxyzine Hydrochloride
- 68071-4530-3 - 30 TABLET, FILM COATED in 1 BOTTLE
- 68071-4530 - Hydroxyzine Hydrochloride
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68071-4530-3 identifies a specific commercial package of 30 tablet, film coated in 1 bottle of Hydroxyzine Hydrochloride, labeled by Nucare Pharmaceuticals,inc.. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Nucare Pharmaceuticals,inc. on October 09, 2012. The current certification is valid through December 31, 2022.
How is this Nucare Pharmaceuticals,inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68071453003. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.